Document is current
Any future updates will be listed below
-
Authors
Gumbleton, Matthew https://orcid.org/0000-0003-4882-4116
Allan, Stephanie
Conway, Hannah
Boucher, Kenneth https://orcid.org/0000-0003-2833-0127
Marvin, James
Hawks, Josiah https://orcid.org/0000-0001-9908-4598
Burnett, William
Van Brocklin, Matthew
Whisenant, Jonathan
Gilcrease, Glynn
Gupta, Sumati https://orcid.org/0000-0001-6271-0831
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03407976 at ClinicalTrials.govDocuments that mention this clinical trial
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
https://doi.org/10.1186/s13104-023-06283-5
-
Funding
Funding for this research was provided by:
National Cancer Institute (5P30CA042014-24)
University of Utah (University of Utah)
Elevar Therapeutics (Elevar Therapeutics)
- License Information
-
More Information
Article History
Received: 12 July 2022
Accepted: 30 January 2023
First Online: 16 February 2023
Declarations
:
: This trial was approved by the University of Utah / Huntsman Cancer Institute institutional review board. All patients provided written informed consent. This trial was registered with ClinicalTrials.gov under the identifier NCT03407976.
: We hereby affirm that all authors that all authors have reviewed the manuscript, concur with the submission and that none of the data herein have been previously reported or are under consideration for publication elsewhere.
: LSK Biopharma / Elevar Therapeutics provided funding support for the current study directly to Huntsman Cancer Institute. University of Utah provided funding for some correlative studies included in the present manuscript. SG has received honoraria from SITC advances in Cancer Immunotherapy as the Salt Lake City Program Organizer and presenter, travel support from QED Biopharmaceutical, as well as funding for other clinical trials from Bristol Myers Squibb, Rexahn, Incyte, Novartis, LSK, Five Prime, Mirati, QED, Debiopharm, Merck, Pfizer, Astra Zeneca, Medimmune, Clovis, Immunocore, and Seattle Genetics. All other authors have no relevant competing interests.
